Fragment-based drug discovery (FBDD) is one strategy of hit identification (hit ID) in the drug discovery process.
Watch the webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec.
Key Learning Objectives:
- How FBDD can help identify novel and potent lead compounds.
- Understand the benefits of FBDD technology compared to high throughput screening (HTS).
- Learn how FBDD is being used as one strategy of hit identification within drug discovery.
Fragments are small molecules with a low molecular weight (less than 250 g/mol). The FBDD technology is based on identifying these small chemical fragments which bind to the biological target, and which are then optimised into lead-like molecules (less than 400 g/mol) and finally into bioavailable drugs.
Chemical diversity space of fragments is relatively small, and thus fragment libraries need only be several thousand compounds in size to provide reasonable sampling of structure space. In contrast, high throughput screening (HTS) of higher molecule weight compounds (400-600 g/mol) generally requires libraries of millions of compounds.
The webinar features the expertise of Andreas Schoop, PhD, Head of Medicinal Chemistry, WuXi AppTec HitS & Moran Jerabek-Willemsen, PhD, Head of Biophysics & Screening, WuXi AppTec HitS.